In this context, we used an AND-gated targeting of PD-L1 and the TAA PSCA on PC3-PSCA/PD-L1 cells to increase the specificity for on-target-on-tumor targeting and reduce the risk of on-target-off-tumor effects. The gene discussed is CD274; the disease is neoplasm.